Literature DB >> 9291879

Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research.

A B Nattinger1, T L McAuliffe, M M Schapira.   

Abstract

To assess the generalizability of the population included in the Surveillance, Epidemiology, and End Results (SEER) tumor registries to the overall United States population, we compared the population of the 198 SEER counties to the population of the 2882 non-SEER counties regarding sociodemographic factors, physician availability, and availability of pertinent hospital resources. The population residing within the SEER areas is more affluent, has lower unemployment, and is substantially more urban than the remainder of the U.S. population (p < 0.001 for each). The SEER areas have fewer general and family practice physicians, but more total nonfederal physicians, general internists, and specialists relevant to cancer care. SEER areas have fewer Joint Commission on Accreditation of Hospitals accredited hospitals, hospital beds, and hospitals with CT scanners, but more hospitals with bone marrow transplantation. The differences between the SEER population and the remainder of the United States, especially SEER's higher socioeconomic status and more urban population, should be considered when generalizing from SEER to the entire country.

Entities:  

Mesh:

Year:  1997        PMID: 9291879     DOI: 10.1016/s0895-4356(97)00099-1

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  55 in total

1.  Representativeness of participants in the cancer care outcomes research and surveillance consortium relative to the surveillance, epidemiology, and end results program.

Authors:  Paul J Catalano; John Z Ayanian; Jane C Weeks; Katherine L Kahn; Mary Beth Landrum; Alan M Zaslavsky; Jeannette Lee; Jane Pendergast; David P Harrington
Journal:  Med Care       Date:  2013-02       Impact factor: 2.983

2.  Survival for older patients with acute myeloid leukemia: a population-based study.

Authors:  Betul Oran; Daniel J Weisdorf
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

3.  Variation in chemotherapy utilization in ovarian cancer: the relative contribution of geography.

Authors:  Daniel Polsky; Katrina A Armstrong; Thomas C Randall; Richard N Ross; Orit Even-Shoshan; Paul R Rosenbaum; Jeffrey H Silber
Journal:  Health Serv Res       Date:  2006-12       Impact factor: 3.402

4.  Epidemiology of Medicare abuse: the example of power wheelchairs.

Authors:  James S Goodwin; Tracy U Nguyen-Oghalai; Yong-Fang Kuo; Kenneth J Ottenbacher
Journal:  J Am Geriatr Soc       Date:  2007-02       Impact factor: 5.562

5.  Managed care market share and primary treatment for cancer.

Authors:  Nancy L Keating; Mary Beth Landrum; Ellen Meara; Patricia A Ganz; Edward Guadagnoli
Journal:  Health Serv Res       Date:  2006-02       Impact factor: 3.402

6.  The frequency of early repeat tests after colonoscopy in elderly medicare recipients.

Authors:  Robert J Richards; Stephen Crystal
Journal:  Dig Dis Sci       Date:  2009-02-25       Impact factor: 3.199

7.  Secular changes in NSAID use and invasive colorectal cancer incidence: an ecological study.

Authors:  Elizabeth B Lamont; Lauren E Dias
Journal:  Cancer J       Date:  2008 Jul-Aug       Impact factor: 3.360

8.  Multimorbidity in women with and without osteoporosis: results from a large US retrospective cohort study 2004-2009.

Authors:  C D O'Malley; N Tran; C Zapalowski; N Daizadeh; T P Olenginski; J A Cauley
Journal:  Osteoporos Int       Date:  2014-05-24       Impact factor: 4.507

9.  Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients.

Authors:  Laura A Hatfield; Haiden A Huskamp; Elizabeth B Lamont
Journal:  J Oncol Pract       Date:  2016-06-28       Impact factor: 3.840

10.  Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status.

Authors:  Albert J Farias; Xianglin L Du
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-05-17       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.